![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 40, 28067-28070, October 1, 1999
From the The myb gene family has three
members, c-myb, A-myb, and B-myb,
which have distinct expression patterns. Analyses of c-myb and A-myb mutant mice have indicated that c-myb
and A-myb are important for hematopoiesis and
spermatogenesis, respectively. However, there has been no evidence for
a role for B-myb in development. To examine the role of
B-myb in development, we generated
B-myb-deficient mice by gene targeting. Although the
heterozygous mutants were healthy, the homozygous mutants died at an
early stage of development, around E4.5-E6.5. In vitro
culture of blastocyst indicated that B-myb is required for
inner cell mass formation. Consistent with the important role of
B-myb in early embryonic development, only B-myb among myb family members was expressed in
embryonic stem cells. These results indicate that each of the three
members of the myb gene family plays a distinct role during development.
The c-myb proto-oncogene is the cellular progenitor of
the v-myb oncogenes carried by the chicken retroviruses AMV
and E26, which transform myelomonocytic hematopoietic cells (1, 2). The
mammalian myb gene family contains two other members,
A-myb and B-myb, in addition to c-myb
(3). These three members display notable homology toward each other in
three regions: the N-terminal DNA-binding domain and two regions in the
C-terminal region (3, 4). The DNA-binding domain in the N-terminal
region of the myb protein (Myb) consists of three imperfect
tandem repeats of 51-52 amino acids, each of which contains a
helix-turn-helix variation motif (4-7). The second and third repeats
are closely packed into the major groove of DNA, and the two
recognition helices in these repeats bind to the specific base
sequence, AACNG, cooperatively (8, 9).
In addition to the N-terminal DNA-binding domain, c-Myb has two
functional domains responsible for transcriptional activation and
negative regulation, respectively (4). The transcriptional activation
domain of c-Myb, which is rich in acidic amino acids, is adjacent to
the DNA-binding domain. Deletion of the negative regulatory domain
(NRD), located in the carboxyl-proximal portion of the molecule,
increases both transactivation and transformation capacities, implying
that this domain normally represses c-Myb activity (4, 10, 11). A-Myb
has a very similar functional domain structure to c-Myb and is the
strongest transcriptional activator among the three members of the
myb gene family (12-15). Compared with c-Myb and A-Myb,
B-Myb is a weaker transcriptional activator (16-18). Although B-Myb
has an acidic transcriptional activation domain located downstream of
the DNA-binding domain, the C-terminal portion appears to be the region
required for transcriptional activation (19, 20). One possible
regulatory mechanism mediated by the C-terminal portion is
phosphorylation by cyclin A-dependent kinase. CyclinA/Cdk2
phosphorylates the C-terminal region of B-Myb and stimulates its
trans-activation capacity (21-24).
Although the three members of myb gene family recognize the
same DNA sequence, they have distinct expression patterns. The level of
c-myb expression is predominantly, although not exclusively, high in immature hematopoietic cells, and its expression is turned off
during terminal differentiation (25-27). Constitutive expression of a
transfected c-myb gene blocks the induced differentiation of
immature erythroid cells (28), and a block of c-myb
expression reduces the proliferation of hematopoietic precursor cells
(29). Furthermore, homozygous c-myb mutant mice are severely
anemic and die in utero because of defective fetal
hematopoiesis (30). In addition to the important role of
c-myb in hematopoietic progenitor cells, c-myb is
also critical for the mitogen-induced proliferation of certain types of
cells such as T lymphocytes (31-33). Unlike c-myb,
A-myb is highly expressed in the developing central nervous system, male germ cells, female breast ductal epithelium, and B
lymphocytes (34). Consistent with its expression in adult testis and
female breast, A-myb-deficient males are infertile because
of a block in spermatogenesis, and null A-myb females show
underdevelopment of breast tissue following pregnancy (35).
In contrast to the restricted expression of c-myb and
A-myb, the cell-type specificity of B-myb
expression is broader in both adult tissues and embryos (3, 36). Like
that of c-myb, the expression of B-myb correlates
with cellular proliferation. B-myb mRNA is not expressed
in resting cells but is induced late in G1 phase, and the
resulting high levels are maintained through S phase (37, 38).
B-myb mRNA levels decrease when HL-60 or U937 cells are
induced to differentiate (38, 39). Inhibition of B-myb
expression by the introduction of a B-myb antisense
construct diminished the cell proliferation of hematopoietic cells and
fibroblasts, but constitutive expression of B-myb induced a
transformed phenotype (39, 40). However, there has been no indication
of a role for B-myb in development.
To understand the physiological role of B-myb, we have
generated B-myb-deficient mice. Analysis of
B-myb-deficient embryos indicates that B-myb is
essential for inner cell mass
(ICM)1 formation in an early
stage of development.
Construction of the Targeting Vector--
The mouse
B-myb genomic clones were isolated from a library derived
from C57BL/6 mice by the standard plaque hybridization procedure. A
15.0-kb genomic DNA subfragment which contains the five exons encoding
amino acids 8-200 was used to generate the targeting vector. The
BglII fragment containing the exon encoding amino acids
94-167 was replaced by a neomycin (neo) cassette driven by
the phosphoglycerate kinase gene promoter. To increase the frequency of
gene targeting, the DT-A (diphtheria toxin-poly(A) signal) cassette for
negative selection was fused to the short arm as described previously
(41).
Generation of B-myb-deficient Mutant Mice--
The ES cells used
were TT2 cells which had been derived from an F1 embryo resulting from
a cross between C57BL/6 and CBA mice (42). The
NotI-linearized targeting vector (100 µg) was
electroporated into 1.0 × 107 TT2 cells. Targeted
clones were selected after 7-10 days growth in the presence of G418
(150 µg/ml) and were then expanded in duplicate 24-well plates. The
homologous nature of the recombination was confirmed by Southern blot
analysis using several restriction enzymes and several probes located
either inside or outside the targeting vector. In addition, three
different primers were used to amplify a 175-bp fragment from the
wild-type allele or a 236-bp fragment from the mutant allele. Chimeras
were produced by injecting about ten ES cells into 40 ICR 8-cell
embryos and transplanting the embryos into the uterus of pseudopregnant
females as described (43). Six- to eight-week-old male progeny with a
high degree of chimerism were derived from three clones and were bred
with C57BL/6 females to produce heterozygous mice capable of
transmitting the targeted allele through the germ line. The mice were
maintained by the Division of Experimental Animal Research, RIKEN.
Genotyping of ES Cells, Embryos, and Animals--
Genomic DNA
was isolated from cultured ES cells, embryos, and tail clippings by
digestion overnight at 55 °C in lysis buffer (10 mM
Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5%
SDS, 0.5 mg/ml proteinase K) followed by RNase A treatment,
phenol-chloroform extraction, and ethanol precipitation. For Southern
blot analysis, genomic DNA (about 20 µg) was digested with
EcoRI and resolved on 0.8% agarose gels. For genotyping of
cultured blastocysts, genomic DNA was isolated from yolk sacs by
digestion for 60 min at 55 °C in lysis buffer (10 mM
Tris-HCl, pH 8.4, 50 mM KCl, 2.5 mM
MgCl2, 0.5% Tween 20, 0.5% Nonidet P-40, 0.5 mg/ml
proteinase K), and then at 94 °C for 10 min to inactivate proteinase
K just prior to PCR analysis. PCR was carried using two of the
following primers: forward B-myb primer,
5'-TGCCTCTGTGCAGTGAGAACATGTGTGTAT-3'; reverse B-myb primer,
5'-GCCTGACGCCTCAATTCTTGTCAGTTTAGG-3'; neo primer,
5'-CGCTACCGGTGGATGTGGAATGTGTGCGAG-3'. Conditions for PCR were 94 °C
for 45 s, 55 °C for 25 s, and 72 °C for 3 min, for 40 cycles.
Detection of B-Myb Protein--
Splenocytes were disrupted in
the hypotonic buffer (10 mM Hepes, pH 7.4, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol) using Dounce homogenizer, and the nuclei
were prepared by centrifugation. The nuclear extract was prepared by
incubating the nuclei with the extraction buffer (20 mM
Hepes, pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 0. 5 mM
dithiothreitol). Western blots were performed using the anti-B-Myb
polyclonal antibody (19) and ECL detection reagents (Amersham Pharmacia Biotech).
Blastocyst Outgrowth Cultures--
Blastocysts from heterozygous
and control mating were flushed from the uterus on 3.5 days post-coitus
as described by Hogan et al. (44). Blastocysts were grown on
4-well culture plates (Nunc) coated with 0.1% gelatin in CMRL1066
medium (Life Technologies, Inc.) supplemented with 15% fetal calf
serum, 1 mM L-glutamine, and 1 mM
sodium pyruvate at 37 °C in a 5% CO2 incubator as
described by Gonda and Hsu (45) and Wu et al. (46). Embryo
morphology was observed each day, and after 5 days blastocysts
outgrowths were photographed. Cells were lysed off the bottom of the
well, and their genotypes were determined by PCR as described above.
The B-myb mutant mice were generated by homologous
recombination in TT-2 ES cells. Exon 5 encoding amino acids 94-167 of
B-Myb, which corresponds to a part of repeats 2 and 3 required for
binding to the Myb-recognition sequence, was replaced with a
neo cassette in the gene-targeting vector (Fig.
1A). Therefore, removal of this exon should lead to a complete loss of DNA-binding activity of
B-Myb. Homologous recombinants were characterized by the appearance of
a 7.0-kb EcoRI fragment with the 3'-probe and a 236-bp
PCR-amplified fragment with the B-myb forward primer and
neo primer (Fig. 1, B and C). Chimeras
were normally obtained from two independent mutant ES clones and mated
with C57BL/6 females to generate F1 heterozygous mutant mice.
Heterozygous (B-myb+/ Heterozygous mice were intercrossed, and the genotypes of resulting
3-weeks-old offspring were determined. Among 212 offspring derived from
two independent germ-line chimeras, no
B-myb Because B-myb is expressed in both the preimplantation
embryos and maternal deciduum (36), the abortive development of
B-myb mutant embryos could result from defects intrinsic to
the embryo or from a breakdown in the signaling between the embryo and
the uterus. To distinguish these two possibilities, embryo day
3.5-blastocysts isolated from heterozygotes intercrosses were grown
in vitro, examined for growth abnormalities, and
subsequently genotyped. By optimizing growth conditions, blastocysts
grown in vitro develop to the egg cylinder stage and can
even be taken to the 8-somite stage (45, 46). The series of
developmental changes that occur during this process have been clearly
delineated. Forty-three blastocysts were individually cultured for 5 days and then photographed and lysed for genotyping. Mutant
homozygotes, heterozygotes, and wild-type embryos were
indistinguishable as embryo day 3.5-blastocysts, attached blastocysts,
or lipid vesicle-containing attached blastocysts (Fig.
2, A-C), indicating that the
B-myb mutation does not affect development prior to
implantation. After 5 days in culture, all the cultured blastocysts of
each genotype (B-myb+/+,
B-myb+/
COMMUNICATION
B-myb Is Required for Inner Cell Mass Formation
at an Early Stage of Development*
§¶,
§
,
**, and
**
Laboratory of Molecular Genetics,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
) mice were identified by
Southern blot and PCR analysis (Fig. 1B). Western blot
analysis showed that the expression level of the 92-kDa B-Myb protein
in spleen was similar between the wild-type and the
B-myb+/
mice (Fig. 1C). This was
confirmed by using the three different anti-B-Myb antibodies (data not
shown). This suggests that a compensatory mechanism plays a role in
maintaining the level of B-Myb protein. Similar observations were
reported so far in other genes (47). The B-Myb protein fragment lacking
the DNA-binding domain encoded by the mutated allele, which can act as
a dominant negative form, was not detected in the
B-myb+/
mice (Fig. 1C).
Heterozygous males and females were phenotypically normal and
fertile.

View larger version (21K):
[in a new window]
Fig. 1.
Generation of
B-myb-deficient mice. A, diagrammatic
representations of the B-myb locus and targeting construct.
Five exons are shown. Exon 1 encodes the initiating methionine, and
exons 2-6 encode amino acids 8-38, 39-62, 63-93, 94-167, and
168-200, respectively. The BglII fragment containing exon 5 was replaced by the neomycin (neo) cassette and is flanked
by 9.0- and 2.5-kilobase homologous sequences on its 5' and 3' side,
respectively. The location of the probe used for Southern blot analyses
is given along with the expected sizes of the hybridizing fragments.
Bg, BglII; E, EcoRI; EV,
EcoRV; BSK, pBluescript II SK vector. B, genomic
Southern blots (B) and PCR (C) analyses of wild
type (+/+), heterozygous (+/
), and homozygous (
/
) mutant mice.
Genomic DNAs were isolated from the tails of mice and digested with
EcoRI for Southern blot analysis. C,
immunodetection of B-Myb protein. Indicated amounts of nuclear extracts
from wild-type (+/+) or B-myb+/
(+/
) mouse
spleen were used for Western blotting with anti-B-Myb antibody.
/
homozygotes were detected, and the
ratio of B-myb+/+ to
B-myb+/
genotypes was 1:2 (data not shown).
The fact that the ratio of B-myb+/+ and
B-myb+/
genotype in the progeny population of
the cross of B-myb+/
and
B-myb+/+ (either male or female) was 1:1
indicated that B-myb
germ cells were not
eliminated during spermatogenesis or oogenesis. Because 98 of the
progeny were from intercrosses between two independent ES cell
line-derived heterozygotes, the lack of B-myb-null progeny could not have been because of homozygosity of an undetected linked mutation inadvertently generated in either of the targeted ES cell
lines. We conclude that homozygosity for the B-myb null
allele is lethal during embryonic development. B-myb is
expressed at similar levels during all stages of embryogenesis (36). As
many of these expression sites may be required for development to
birth, we examined embryos of heterozygotes intercrosses on different days of gestation (Table I). Among 32 phenotypically normal embryo day 3.5 (3.5 days post-coitus) blastocyst,
6 (19%) were homozygous for the mutant allele, indicating that
B-myb is not essential for embryogenesis before uterine
implantation. At embryo day 6.5-7.5, all decidua were externally
indistinguishable, but dissection revealed that 8 of 51 (16%)
implantation sites lacked discernible embryos, yolk sacs, and
ectoplacental cones. Of 65 phenotypically normal embryo day 6.5-7.5
embryos subjected to genotyping, none were homozygous mutants.
Consistent with this, none of the phenotypically normal embryo day
8.5-10.5 embryos were homozygous mutants, whereas an additional nine
implantation sites (12% of the total) were undergoing resorption. The
high frequency of abortive postimplantation development and lack of
older B-myb null embryos indicate that B-myb null
embryos degenerate shortly after uterine implantation.
Genotypes of litters from heterozygous intercross
), and homozygous
(
/
) embryos is indicated. The genotypes of resorbed embryos could
not be determined.
, and
B-myb
/
) gave rise to an adherent sheet of
trophectoderm-like cells, including trophoblastic giant cells (Fig. 2,
D-F). However, B-myb
/
blastocysts showed severely impaired proliferation of the ICM. As
summarized in Fig. 2G, the null genotype was never
associated with robust outgrowths of the ICM (as in Fig. 2,
D and E) and was the only genotype associated
with undetectable ICM outgrowth (as in Fig. 2F). The
developmental defects of B-myb null embryos in
vivo and in vitro demonstrate that B-myb is
essential for growth of the ICM in the postimplantation phase of
development.

View larger version (68K):
[in a new window]
Fig. 2.
In vitro outgrowth cultures of
intercross embryos. Blastocysts were flushed out of the uterus of
a B-myb+/
female 3.5 days after mating with a
B-myb+/
male and were grown in
vitro. Embryo day 3.5 wild-type (A), heterozygous
(B), and homozygous (C) blastocysts appear
normal. Outgrowth of polyploid trophectoderm (TE) cells was
observed in all the cultures of wild-type (D), heterozygous
(E), and homozygous (F) blastocysts. A well
developed ICM is evident in the wild-type and heterozygous cultures and
is composed of an outer primitive endoderm layer and an inner core
ectoderm cells. No distinct ICM is seen in the homozygous culture.
G, histogram summary of blastocyst outgrowth. The number of
blastocysts with each genotype is shown by a bar
graph.
For the purpose of generating chimeras using
B-myb
/
ES cells, we tried to generate
B-myb
/
homozygous mutant ES cells by
increasing G418 concentration but failed. These results suggest that
B-myb is essential for the proliferation of ES cells. We
examined the expression of the three members of myb gene
family in ES cells by Northern blotting. The 2.6-kb B-myb
mRNA was highly expressed in ES cells, whereas neither the
c-myb nor A-myb mRNAs was detected
(Fig. 3). Thus, only B-myb among the three members of myb gene family is expressed in
ES cells, which is consistent with the speculation that
B-myb is required for ES cell propagation.
|
| |
DISCUSSION |
|---|
|
|
|---|
In this study, we generated a null mutation of the B-myb gene by homologous recombination in mouse ES cells. The B-myb mutation drastically affected embryonic growth, resulting in lethality before day 6.5 of gestation.
One possible explanation for the early lethality of the
B-myb
/
embryo is impaired G1/S
transition in cell cycle. B-myb has been reported to have an
important role as one of the target genes of E2F during
G1/S transition (48). The trophectoderm appeared more
resistant to B-myb depletion than ICM cells as shown by the in vitro outgrowth experiments. Because of their rapid
proliferation, ICM cells are much more sensitive to metabolic
inhibitors than trophoblast cells. Exposure of blastocysts in
vitro to x-ray or ultraviolet irradiation interferes with the
proliferation of the ICM cells but has little effect on the trophoblast
outgrowth (49). These irradiations also abrogate the G1/S
transition in the cell cycle. The sensitivity of ICM to these
irradiations appears to be consistent with the effect of
B-myb depletion on ICM proliferation.
B-myb is highly expressed in proliferating mouse ES cells
and in proliferating cells in various regions of the embryo (36), suggesting that B-Myb might be acting in these cells as a positive regulator of cell growth. In addition, we were unsuccessful in our
attempts to obtain viable ES cells homozygous for the B-myb mutation, supporting the role of B-Myb in cell growth identified in vivo and in vitro. Thus, the B-myb
gene may play, at some developmental stages and in specific tissues, a
positive role in control of cell growth. If B-myb plays a
role in the control of cellular proliferation, its inactivation should
cause lethality at very early developmental stages. Nevertheless,
embryo day 3.5 B-myb
/
blastocysts appeared
normal, although their proliferative abilities in vitro were
dramatically reduced. The in vivo survival of
B-myb-/mutant embryos until embryo day 3.5 could
be because of persistence of sufficient maternal B-myb
protein or mRNA for development of the embryo until the early
gastrulation stages.
The distinct phenotype of each member of the myb gene
family, as deduced from the specific defects of A-,
B-, and c-myb mutant mice in spermatogenesis, ICM
formation, and hematopoiesis, respectively, appears to be related to
their expression patterns. In some tissues, however, multiple members
of the myb gene family are expressed. This raises the
possibility that each member may have a distinct function and that each
may regulate cell growth through a different mechanism. Rescuing the
early lethality suffered by B-myb null embryos by generating
the tissue-specific deficient mutant mice could provide insights into
the other functions of B-myb.
| |
FOOTNOTES |
|---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ These authors contributed equally to this work.
¶ Supported by the Special Researcher's Basic Science Program.
Supported by a Science and Technology Agency Fellowship.

To whom correspondence should be addressed. Tel.:
81-298-36-9031; Fax: 81-298-36-9030; E-mail:
sishii@rtc.riken.go.jp.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: ICM, inner cell mass; bp, base pair(s); PCR, polymerase chain reaction.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Roussel, M., Saule, S., Lagrou, C., Beug, H., Graf, T., and Stehelin, D. (1979) Nature 281, 452-455[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Klempnauer, K.-H., Gonda, T., J., and Bishop, J. M. (1982) Cell 31, 453-463[CrossRef][Medline] [Order article via Infotrieve] |
| 3. |
Nomura, N.,
Takahashi, M.,
Matsui, M.,
Ishii, S.,
Date, T.,
Sasamoto, S.,
and Ishizaki, R.
(1988)
Nucleic Acids Res.
16,
11075-11089 |
| 4. |
Sakura, H.,
Kanei-Ishii, C.,
Nagase, T.,
Nakagoshi, H.,
Gonda, T. J.,
and Ishii, S.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
5758-5762 |
| 5. |
Tanikawa, J.,
Yasukawa, T.,
Enari, M.,
Ogata, K.,
Nishimura, Y.,
Ishii, S.,
and Sarai, A.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
9320-9324 |
| 6. |
Ogata, K.,
Hojo, H.,
Aimoto, S.,
Nakai, T.,
Nakamura, H.,
Sarai, A.,
Ishii, S.,
and Nishimura, Y.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
6428-6432 |
| 7. | Ogata, K., Morikawa, S., Nakamura, H., Hojo, H., Yoshimura, S., Zhang, R., Aimoto, S., Ametani, Y., Hirata, Z.,., Sarai, A., Ishii, S., and Nishimura, Y. (1995) Nat. Struct. Biol. 2, 309-320[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Ogata, K., Morikawa, S., Nakamura, H., Sekikawa, A., Inoue, T., Kanai, H., Sarai, A., Ishii, S., and Nishimura, Y. (1994) Cell 79, 639-648[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Biedenkapp, H., Borgmeyer, U., Sippel, A. E., and Klempnauer, K.-H. (1988) Nature 335, 835-837[CrossRef][Medline] [Order article via Infotrieve] |
| 10. |
Kanei-Ishii, C.,
Macmillan, E. M.,
Nomura, T.,
Sarai, A.,
Ramsay, R. G.,
Aimoto, S.,
Ishii, S.,
and Gonda, T. J.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
3088-3092 |
| 11. |
Dubendorff, J. W.,
Whittaker, L. J.,
Eltman, J. T.,
and Lipsick, J. S.
(1992)
Genes Dev.
6,
2524-2535 |
| 12. | Foos, G., Grimm, S., and Klempnauer, K.-H. (1994) Oncogene 9, 2481-2488[Medline] [Order article via Infotrieve] |
| 13. | Golay, J., Loffarelli, L., Luppi, M., Castellano, M., and Introna, M. (1994) Oncogene 9, 2469-2479[Medline] [Order article via Infotrieve] |
| 14. | Takahashi, T., Nakagoshi, H., Sarai, A., Nomura, N., Yamamoto, T., and Ishii, S. (1995) FEBS Lett. 358, 89-96[CrossRef][Medline] [Order article via Infotrieve] |
| 15. |
Oh, I. H.,
and Reddy, E. P.
(1997)
J. Biol. Chem.
272,
21432-21443 |
| 16. |
Mizuguchi, G.,
Nakagoshi, H.,
Nagase, T.,
Nomura, N.,
Date, T.,
Ueno, Y.,
and Ishii, S.
(1990)
J. Biol. Chem.
265,
9280-9284 |
| 17. | Nakagoshi, H., Kanei-Ishii, C., Sawazaki, T., Mizuguchi, G., and Ishii, S. (1992) Oncogene 7, 1233-1240[Medline] [Order article via Infotrieve] |
| 18. |
Nakagoshi, H.,
Takemoto, Y.,
and Ishii, S.
(1993)
J. Biol. Chem.
268,
14161-14167 |
| 19. | Tashiro, S., Takemoto, Y., Handa, H., and Ishii, S. (1995) Oncogene 10, 1699-1707[Medline] [Order article via Infotrieve] |
| 20. |
Oh, I. H.,
and Reddy, E. P.
(1998)
Mol. Cell. Biol.
18,
499-511 |
| 21. |
Sala, A.,
Kundu, M.,
Casella, I.,
Engelhard, A.,
Calabretta, B.,
Grasso, L.,
Paggi, M. G.,
Giordano, A.,
Watson, R. J.,
Khalili, K.,
and Peschle, C.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
532-536 |
| 22. | Lane, S., Farlie, P., and Watson, R. (1997) Oncogene 14, 2445-2453[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Ziebold, U., Bartsch, O., Marais, R., Ferrari, S., and Klempnauer, K.-H. (1997) Curr. Biol. 7, 253-260[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Saville, M. K., and Watson, R. J. (1998) Oncogene 17, 2679-2689[CrossRef][Medline] [Order article via Infotrieve] |
| 25. |
Westin, E. H.,
Gallo, G. C.,
Arya, S. K.,
Eva, A.,
Souza, L. M.,
Baluda, M. A.,
Aaronson, S. A.,
and Wong-Staal, F.
(1982)
Proc. Natl. Acad. Sci. U. S. A.
79,
2194-2198 |
| 26. | Gonda, T. J., and Metcaf, D. (1984) Nature 310, 249-251[CrossRef][Medline] [Order article via Infotrieve] |
| 27. |
Duprey, S. P.,
and Boettiger, D.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
6937-6941 |
| 28. |
Todokoro, K.,
Watson, R. J.,
Higo, H.,
Amanuma, H.,
Kuramochi, S.,
Yanagisawa, H.,
and Ikawa, Y.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
8900-8904 |
| 29. |
Gewirtz, A. M.,
and Calabretta, B.
(1988)
Science
242,
1303-1306 |
| 30. | Mucenski, M. L., McLain, K., Kier, A. B., Swerdlow, S. H., Schereiner, C. M., Miller, T. A., Pietryga, D. W., Scott, W. J., and Potter, S. S. (1991) Cell 65, 677-689[CrossRef][Medline] [Order article via Infotrieve] |
| 31. |
Stern, J. B.,
and Smith, K. A.
(1986)
Science
233,
203-206 |
| 32. |
Badiani, P.,
Corbella, P.,
Kioussis, D.,
Marvel, J.,
and Weston, K.
(1994)
Genes Dev.
8,
770-782 |
| 33. |
Allen, R. D., III,
Bender, T. P.,
and Siu, G.
(1999)
Genes Dev.
13,
1073-1078 |
| 34. | Trauth, K., Mutschler, B., Jenkins, N. A., Gilbert, D. J., Copelend, N. G., and Klempnauer, K.-H. (1994) EMBO J. 13, 5994-6005[Medline] [Order article via Infotrieve] |
| 35. | Toscani, A., Mettus, R. V., Coupland, R., Simpkins, H., Letvin, J., Orth, J., Hatton, K. S., and Reddy, E. P. (1997) Nature 386, 713-717[CrossRef][Medline] [Order article via Infotrieve] |
| 36. | Sitzman, J., Noben-Trauth, K., Kamano, H., and Klempnauer, K.-H. (1996) Oncogene 12, 1889-1894[Medline] [Order article via Infotrieve] |
| 37. |
Golay, J.,
Capucci, A.,
Arsura, M.,
Castellano, M.,
Rizzo, V.,
and Introna, M.
(1991)
Blood
77,
149-158 |
| 38. | Reiss, K., Travali, S., Calabretta, B., and Baserga, R. (1991) J. Cell. Physiol. 148, 338-343[CrossRef][Medline] [Order article via Infotrieve] |
| 39. |
Arsura, M.,
Introna, M.,
Passerini, F.,
Mantovani, A.,
and Golay, J.
(1992)
Blood
79,
2708-2716 |
| 40. |
Sala, A.,
and Calabretta, B.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
10415-10419 |
| 41. | Yagi, T., Nada, S., Watanabe, N., Tamemoto, H., Kohmura, N., Ikawa, Y., and Aizawa, S. (1993) Anal. Biochem. 214, 77-86[CrossRef][Medline] [Order article via Infotrieve] |
| 42. | Yagi, T., Tokunaga, T., Furuta, Y., Nada, S., Yoshida, M., Tsukada, T., Saga, Y., Takeda, T., Ikawa, Y., and Aizawa, S. (1993) Anal. Biochem. 214, 70-76[CrossRef][Medline] [Order article via Infotrieve] |
| 43. |
Tanaka, Y.,
Naruse, I.,
Maekawa, T.,
Masuya, H.,
Shiroishi, T.,
and Ishii, S.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
10215-10220 |
| 44. | Hogan, B., Constantini, F., and Lacy, E. (1986) Manipulating the Mouse Embryo: A Laboratory Manual , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY |
| 45. | Gonda, M. A., and Hsu, Y.-C. (1980) J. Embryol. Exp. Morphol. 56, 23-39[Medline] [Order article via Infotrieve] |
| 46. | Wu, T.-C., Wan, Y.-J., and Damjanov, I. (1981) J. Embryol. Exp. Morphol. 65, 105-117[Medline] [Order article via Infotrieve] |
| 47. |
Minamisawa, S.,
Gu, Y.,
Ross, J., Jr.,
Chien, K. R.,
and Chen, J.
(1999)
J. Biol. Chem.
274,
10066-10070 |
| 48. | Lam, E. W.-F., and Watson, R. J. (1993) EMBO J. 12, 2705-2713[Medline] [Order article via Infotrieve] |
| 49. | Rowinski, J., Solter, D., and Koprowski, H. (1975) J. Exp. Zool. 192, 133-142[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
J. P. O'Rourke and S. A. Ness Alternative RNA Splicing Produces Multiple Forms of c-Myb with Unique Transcriptional Activities Mol. Cell. Biol., March 15, 2008; 28(6): 2091 - 2101. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wen, L. Andrejka, J. Ashton, R. Karess, and J. S. Lipsick Epigenetic regulation of gene expression by Drosophila Myb and E2F2-RBF via the Myb-MuvB/dREAM complex Genes & Dev., March 1, 2008; 22(5): 601 - 614. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Niwa How is pluripotency determined and maintained? Development, February 15, 2007; 134(4): 635 - 646. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pilkinton, R. Sandoval, J. Song, S. A. Ness, and O. R. Colamonici Mip/LIN-9 Regulates the Expression of B-Myb and the Induction of Cyclin A, Cyclin B, and CDK1 J. Biol. Chem., January 5, 2007; 282(1): 168 - 175. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Garcia and J. Frampton The transcription factor B-Myb is essential for S-phase progression and genomic stability in diploid and polyploid megakaryocytes J. Cell Sci., April 15, 2006; 119(8): 1483 - 1493. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kurahashi, T. Nomura, C. Kanei-Ishii, Y. Shinkai, and S. Ishii The Wnt-NLK Signaling Pathway Inhibits A-Myb Activity by Inhibiting the Association with Coactivator CBP and Methylating Histone H3 Mol. Biol. Cell, October 1, 2005; 16(10): 4705 - 4713. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Blanc, J. O. Henderson, E. P. Newberry, S. Kennedy, J. Luo, and N. O. Davidson Targeted Deletion of the Murine apobec-1 Complementation Factor (acf) Gene Results in Embryonic Lethality Mol. Cell. Biol., August 15, 2005; 25(16): 7260 - 7269. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Nakano, A. A. Paucar, R. Bajpai, J. D. Dougherty, A. Zewail, T. K. Kelly, K. J. Kim, J. Ou, M. Groszer, T. Imura, et al. Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation J. Cell Biol., August 1, 2005; 170(3): 413 - 427. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Santilli, R. Schwab, R. Watson, C. Ebert, B. J. Aronow, and A. Sala Temperature-dependent Modification and Activation of B-MYB: IMPLICATIONS FOR CELL SURVIVAL J. Biol. Chem., April 22, 2005; 280(16): 15628 - 15634. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Davidson, R. Tirouvanziam, L. A. Herzenberg, and J. S. Lipsick Functional Evolution of the Vertebrate Myb Gene Family: B-Myb, but Neither A-Myb nor c-Myb, Complements Drosophila Myb in Hemocytes Genetics, January 1, 2005; 169(1): 215 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Lipsick synMuv verite--Myb comes into focus Genes & Dev., December 1, 2004; 18(23): 2837 - 2844. [Full Text] [PDF] |
||||
![]() |
W. Lei, J. J. Rushton, L. M. Davis, F. Liu, and S. A. Ness Positive and Negative Determinants of Target Gene Specificity in Myb Transcription Factors J. Biol. Chem., July 9, 2004; 279(28): 29519 - 29527. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Joaquin and R. J. Watson The Cell Cycle-regulated B-Myb Transcription Factor Overcomes Cyclin-dependent Kinase Inhibitory Activity of p57KIP2 by Interacting with Its Cyclin-binding Domain J. Biol. Chem., November 7, 2003; 278(45): 44255 - 44264. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Manak, N. Mitiku, and J. S. Lipsick Mutation of the Drosophila homologue of the Myb protooncogene causes genomic instability PNAS, May 28, 2002; 99(11): 7438 - 7443. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. Johnson, T. K. Johnson, M. Desler, T. A. Luster, T. Nowling, R. E. Lewis, and A. Rizzino Effects of B-Myb on Gene Transcription. PHOSPHORYLATION-DEPENDENT ACTIVITY AND ACETYLATION BY p300 J. Biol. Chem., February 1, 2002; 277(6): 4088 - 4097. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bergholtz, T. O. Andersen, K. B. Andersson, J. Borrebak, B. Luscher, and O. S. Gabrielsen The highly conserved DNA-binding domains of A-, B- and c-Myb differ with respect to DNA-binding, phosphorylation and redox properties Nucleic Acids Res., September 1, 2001; 29(17): 3546 - 3556. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Powzaniuk, R. Trotta, M. J. Loza, A. Harth, R. V. Iozzo, L. C. Eisenlohr, B. Perussia, and B. Calabretta B-Myb Overexpression Results in Activation and Increased Fas/Fas Ligand-Mediated Cytotoxicity of T and NK Cells J. Immunol., July 1, 2001; 167(1): 242 - 249. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||